Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Long-Term Investments (2017 - 2025)

Syndax Pharmaceuticals (SNDX) has 5 years of Long-Term Investments data on record, last reported at $62.6 million in Q2 2025.

  • For Q2 2025, Long-Term Investments rose 112.18% year-over-year to $62.6 million; the TTM value through Jun 2025 reached $62.6 million, up 112.18%, while the annual FY2024 figure was $119.5 million, 300.68% up from the prior year.
  • Long-Term Investments reached $62.6 million in Q2 2025 per SNDX's latest filing, down from $89.9 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $119.5 million in Q4 2024 and bottomed at $5.5 million in Q4 2022.
  • Average Long-Term Investments over 4 years is $41.5 million, with a median of $24.5 million recorded in 2023.
  • Peak YoY movement for Long-Term Investments: skyrocketed 445.42% in 2023, then tumbled 36.14% in 2024.
  • A 4-year view of Long-Term Investments shows it stood at $5.5 million in 2022, then surged by 445.42% to $29.8 million in 2023, then skyrocketed by 300.68% to $119.5 million in 2024, then plummeted by 47.6% to $62.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $62.6 million in Q2 2025, $89.9 million in Q1 2025, and $119.5 million in Q4 2024.